These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 15986273

  • 1. [Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
    Olivier Pascual N, Calvo JM, Abelairas Gómez JM.
    Arch Soc Esp Oftalmol; 2005 Jun; 80(6):331-8. PubMed ID: 15986273
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Perioperative intensity-modulated brachytherapy for refractory orbital rhabdomyosarcomas in children.
    Strege RJ, Kovács G, Meyer JE, Holland D, Claviez A, Mehdorn MH, Interdisciplinary Group of Orbitazentrum UK S-H.
    Strahlenther Onkol; 2009 Dec; 185(12):789-98. PubMed ID: 20013088
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB.
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [Abstract] [Full Text] [Related]

  • 5. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR.
    J Clin Oncol; 2011 Apr 01; 29(10):1312-8. PubMed ID: 21357783
    [Abstract] [Full Text] [Related]

  • 6. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Ermoian RP, Breneman J, Walterhouse DO, Chi YY, Meza J, Anderson J, Hawkins DS, Hayes-Jordan AA, Parham DM, Yock TI, Donaldson SS, Wolden SL.
    Pediatr Blood Cancer; 2017 Sep 01; 64(9):. PubMed ID: 28548706
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma.
    Venkitaraman R, Affolter A, Ahmed M, Thomas V, Pritchard-Jones K, Sharma AK, Marais R, Nutting CM.
    Acta Oncol; 2008 Sep 01; 47(3):469-72. PubMed ID: 18348005
    [No Abstract] [Full Text] [Related]

  • 9. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM.
    J Clin Oncol; 2000 Jun 01; 18(12):2427-34. PubMed ID: 10856103
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease.
    Gandhi PD, Fleming JC, Haik BG, Wilson MW.
    Ophthalmic Plast Reconstr Surg; 2011 Jun 01; 27(4):241-6. PubMed ID: 21242849
    [Abstract] [Full Text] [Related]

  • 13. Brachytherapy as part of the multidisciplinary treatment of childhood rhabdomyosarcomas of the orbit.
    Blank LE, Koedooder K, van der Grient HN, Wolffs NA, van de Kar M, Merks JH, Pieters BR, Saeed P, Baldeschi L, Freling NJ, Koning CC.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1463-9. PubMed ID: 19864080
    [Abstract] [Full Text] [Related]

  • 14. Orbital rhabdomyosarcoma in Noonan syndrome.
    Jung A, Bechthold S, Pfluger T, Renner C, Ehrt O.
    J Pediatr Hematol Oncol; 2003 Apr 01; 25(4):330-2. PubMed ID: 12679651
    [Abstract] [Full Text] [Related]

  • 15. 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
    Indelicato DJ, Rotondo RL, Mailhot Vega RB, Uezono H, Bradfield S, Agarwal V, Hol ML, Bradley JA.
    Acta Oncol; 2019 Oct 01; 58(10):1404-1409. PubMed ID: 31530120
    [Abstract] [Full Text] [Related]

  • 16. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 4-2004. A nine-month-old boy with an orbital rhabdomyosarcoma.
    Friedmann AM, Tarbell NJ, Schaefer PW, Hoch BL.
    N Engl J Med; 2004 Jan 29; 350(5):494-502. PubMed ID: 14749459
    [No Abstract] [Full Text] [Related]

  • 17. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC.
    J Clin Oncol; 2012 Jul 10; 30(20):2457-65. PubMed ID: 22665534
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of embryonal rhabdomyosarcoma of the sinus and orbit with chemotherapy, radiation, and endoscopic surgery.
    Luu QC, Lasky JL, Moore TB, Nelson S, Wang MB.
    J Pediatr Surg; 2006 Jun 10; 41(6):e15-7. PubMed ID: 16769322
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.